Abstracts tagged "IL-6"

Abstract Number: 1621 • 2014 ACR/ARHP Annual Meeting
A Shift Towards Trans-Signalling Explains Relatively Low CRP Despite an Active Interleukin-6 (IL-6)/IL-6-Receptor (IL-6R) System in SLE
Martyna Skwarek, Babett Heschel, Julia Fantana and Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany
Background/Purpose IL-6 has been found increased in SLE, while CRP, which is directly stimulated by IL-6, usually remains low. We therefore analyzed the IL-6/ IL-6…
Abstract Number: 1469 • 2014 ACR/ARHP Annual Meeting
Methotrexate Treatment Reduces Serum IL-6 Level By Decreasing a CD14brightCD16+ Intermediate Non-Classical Subset of Monocytes in RA Patients
Masako Tsukamoto¹, Keiko Yoshimoto², Noriyuki Seta³, Katsuya Suzuki² and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine, Keio university, Tokyo, Japan
Background/Purpose It is well known that circulating monocytes are the source of inflammatory cytokines, such as IL-6 and TNFα and newly divided into three subsets…
Abstract Number: 1468 • 2014 ACR/ARHP Annual Meeting
Mechanism of Effectiveness of IL-6 Blockade for Reduction of SAA Production and Amyloid a Deposition in AA Amyloidosis Patients with RA
Kazuyuki Yoshizaki, Osaka University, Osaka, Japan
Background/Purpose AA amyloidosis is a serious complication of chronic inflammatory and infectious diseases resulting from the deposition of amyloid A protein. Serum amyloid A (SAA),…
Abstract Number: 3001 • 2014 ACR/ARHP Annual Meeting
Targeting IL-6 By Both Passive or Active Immunization Strategies Prevents Inflammation-Driven Skin Fibrosis
Jerome Avouac¹, Lucille Desallais², Maxime Fréchet³, Muriel Elhai³, Jean François Zagury² and Yannick Allanore¹, ¹Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ²Chaire de Bioinformatique, Laboratoire Génomique, Bioinformatique et Applications, EA 4627, Conservatoire National des Arts et Métiers, Paris, France, ³INSERM U1016, Cochin Institute, Paris, France
Background/Purpose: Interleukin 6 (IL-6) is a pleiotropic cytokine involved in inflammatory and autoimmune processes. Preliminary data have suggested that IL-6 might contribute to systemic sclerosis…
Abstract Number: 1015 • 2014 ACR/ARHP Annual Meeting
Mir-9/MCPIP1 Axis Mediated Regulation of IL-6 Expression in Osteoarthritis Chondrocytes
Tariq Haqqi¹, Abdul Haseeb² and Mohammad Shahidul Makki², ¹Anatomy & Neurobiology, Northeast Ohio Medical University, Rootstown, OH, ²Anatomy and Neurobiology, Northeast Ohio Medical University (NEOMED), Rootstown, OH
Background/Purpose Post-transcriptional regulation of cytokine expression is important for maintaining tissue integrity. MCPIP1 was identified as a novel protein, which destabilizes inflammatory cytokines mRNAs via…
Abstract Number: 2905 • 2014 ACR/ARHP Annual Meeting
The IL-6/Th17 Axis Promotes Autoantibody-Associated Autoimmune Valvular Carditis in Mice
Jennifer L. Auger¹, Brianna J. Engelson², Yaya Wang³, Erik J. Peterson⁴ and Bryce A. Binstadt⁵, ¹Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, ²Pediatrics, University of Minnesota, Minneapolis, MN, ³Medicine, University of Minnesota, Minneapolis, MN, ⁴University of Minnesota, Minneapolis, MN, ⁵Pediatric Rheumatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Autoimmune valvular carditis occurs in patients with systemic lupus erythematosus, rheumatoid arthritis and rheumatic fever, but the pathogenic mechanisms remain incompletely defined. Spontaneous autoimmune…
Abstract Number: 1014 • 2014 ACR/ARHP Annual Meeting
Harpagide, a Low Molecular Weight Natural Product, Suppresses IL-1â-Induced IL-6 Expression By Blocking the Activation of p38 MAPK and Transcription Factors CEBPâ and AP-1 in Primary Human Osteoarthritis Chondrocytes
Abdul Haseeb¹ and Tariq Haqqi², ¹Anatomy and Neurobiology, Northeast Ohio Medical University (NEOMED), Rootstown, OH, ²Anatomy & Neurobiology, Northeast Ohio Medical University, Rootstown, OH
Background/Purpose: There is growing evidence that shows the involvement of IL-6 in cartilage degradation during OA. Significant correlation between IL-6 levels in serum as well…
Abstract Number: 2877 • 2014 ACR/ARHP Annual Meeting
Novel Function of Tocilizumab As a Modulator of Interleukin-27-Mediated Anti-Inflammatory Responses
Misato Hashizume¹, Jun Kikuchi², Keiko Yoshimoto² and Tsutomu Takeuchi², ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose The immunological roles of interleukin 27 (IL-27) have been reported in the function of regulatory T cells (Treg), monocytes and osteoclasts, and these cells…
Abstract Number: 952 • 2014 ACR/ARHP Annual Meeting
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Evaluate the Efficacy and Safety of Clazakizumab, an Anti-IL-6 Monoclonal Antibody, in Adults with Active Psoriatic Arthritis
Philip J. Mease¹, A B Gottlieb², A Berman³, E Drescher⁴, J Xing⁵, S Banerjee⁵ and R Wong⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ³Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁴Csolnoky Ferenc Hospital, Veszprém, Hungary, ⁵Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: New treatment options for psoriatic arthritis (PsA) are needed and interleukin-6 (IL-6), a cytokine with a central role in chronic inflammation, is a potential…
Abstract Number: 2823 • 2014 ACR/ARHP Annual Meeting
Comparable Efficacy with Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Roy Fleischmann^1,2, Dennis L. Decktor³, Chunpeng Fan⁴, Hubert Van Hoogstraten⁵ and Mark C Genovese⁶, ¹Metroplax Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Biostatistics, Sanofi, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose For patients with prior exposure to tumor necrosis factor-α inhibitor (TNF-I), the likelihood of response to subsequent treatment with a TNF-I declines with the…
Abstract Number: 784 • 2014 ACR/ARHP Annual Meeting
Novel Inhibitory Effects of Mast Cells in Aortitis Involves Aortic Expression of Suppressor of Cytokine Signaling-1
Jason Springer¹, Vineesh Raveendran², Donald Smith³, Mehrdad Maz⁴ and Kottarappat Dileepan², ¹Department of Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Department of Medicine, University of Kansas Medical Center, Kansas City, KS, ³University of Kansas Medical Center, Kansas City, KS, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose Early in the pathogenesis of Giant Cell Arteritis (GCA) dendritic cells interact with T cells of both Th1 and Th17 origin. IL-6; released by…
Abstract Number: 2824 • 2014 ACR/ARHP Annual Meeting
A Profile of the Efficacy of Sarilumab Plus Methotrexate in Rheumatoid Arthritis Patients: Results of a 52-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Arthur Kavanaugh¹, Dennis L. Decktor², Chunpeng Fan³, Janet van Adelsberg², Renata Martincova⁴ and Mark C. Genovese⁵, ¹University of California San Diego, La Jolla, CA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Biostatistics, Sanofi, Bridgewater, NJ, ⁴Sanofi Czech Republic, Prague, Czech Republic, ⁵Stanford University Medical Center, Palo Alto, CA
Background/Purpose Interleukin-6 (IL-6) regulates a diverse array of activities that may underlie systemic and local symptoms of rheumatoid arthritis (RA). The efficacy of sarilumab, a…
Abstract Number: 497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs
Thomas Dörner¹, Hans-Peter Tony², Gerd Burmester¹, Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kästner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, Sylke Wagner⁸, Marvin A. Peters⁹ and Christoph Iking-Konert¹⁰, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University Clinic Wuerzburg, Wuerzburg, Germany, ³University Clinic Munich, Munich, Germany, ⁴Rheumatology Practice, Ludwigsfelde, Germany, ⁵MVZ Out-patient Rheumatogy Unit Erfurt, Erfurt, Germany, ⁶Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, ⁷Rheumatology Practice, Aachen, Germany, ⁸Practice for Internal Medicine specialized in Rheumatology, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰University Clinic Hamburg-Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluated a sequential exposure to 2 defined biologics under rigorous study conditions within a homogeneous population of biological naïve patients (pts)…
Abstract Number: 1403 • 2013 ACR/ARHP Annual Meeting
Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2) Is Expressed In a TNF-Dependent Manner In RA Synovial Tissues
Borbala Aradi¹, Masaru Kato¹, Mária Filková², Stephanie Kasper³, Kerstin Klein¹, Michael Bader¹, Michael Scharl³, Beat A Michel⁴, Renate E Gay¹, Edit I Buzas⁵, Steffen Gay¹ and Astrid Jüngel¹, ¹Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ³Division of Gastroenterology and Hepatology, University Hospital Zürich and Zürich Center for Integrative Human Physiology, Zurich, Switzerland, ⁴Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ⁵Semmelweis University, Department of Genetics, Cell- and Immunobiology, Budapest, Hungary
Background/Purpose: Protein Tyrosine Phosphatase Non-receptor Type 2 (PTPN2) is a protein phosphatase that has been associated with the development of autoimmune diseases in GWA studies.…
Abstract Number: 1380 • 2013 ACR/ARHP Annual Meeting
Histone Modifications In The Interluekin-6 Gene Promoter Region Of Rheumatoid Arthritis Synovial Fibroblasts
Takuma Tsuzuki Wada^1,2, Yasuto Araki^1,2, Kazuhiro Yokota¹, Fumihiko Miyoshi¹, Kojiro Sato¹ and Toshihide Mimura^1,2, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: , Rheumatoid arthritis (RA) is a disease of unknown origin, which develops continuous inflammation and progressive joint destruction resulting from an autoimmune response mainly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].